Aurofac - General Information
A tetracycline with a 7-chloro substitution.
Pharmacology of Aurofac
Aurofac is a tetracycline broad-spectrum antibiotic. It is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by the "active transport" process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed. It inhibits cell growth by inhibiting translation.
Aurofac for patients
Lymecycline is an antibiotic. It should not be administered to pregnant women or children below the age of 8 years. Patients with kidney or liver disease should use it with caution. Patients who are pregnant or breastfeeding should discuss about the risks with the doctors.
Patients may experience the following signs/symptoms while taking Lymecycline:
- Visual disturbances
- Inflammation of the pancreas
- Inflammation of the large intestine
- Damage to the liver
- Nausea and vomiting
- Abnormal reaction of the skin to light, usually a rash
Patients should be advised not to take any indigestion remedies, iron or zinc supplements at the same time as this medicine. Take them at least two hours before or two hours after lymecycline.
The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
Oral contraceptives may be less effective while you are taking lymecycline.
Lymecycline should not be used in children under 12 years of age, patients with long-term inflammation of skin and organs, and patients who are allergic to lymecycline.
Additional information about Aurofac
Aurofac Indication: For the treatment of infections and to treat acne. It may also be used to treat urinary tract infections, gum disease, and other bacterial infections such as gonorrhea and chlamydia. Aurofac is also used commonly as a prophylactic treatment for infection by Bacillus anthracis (anthrax). It is also effective against Yersinia pestis and malaria and is also prescribed for the treatment of Lyme disease.
Mechanism Of Action: Aurofac inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Aurofac is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. Cells become resistant to lymecycline by at least two mechanisms: efflux and ribosomal protection. In efflux, a resistance gene encodes a membrane protein that actively pumps lymecycline out of the cell. This is the mechanism of action of the tetracycline resistance gene on the artificial plasmid pBR322. In ribosomal protection, a resistance gene encodes a protein which binds to the ribosome and prevents lymecycline from acting on the ribosome.
Drug Interactions: Not Available
Food Interactions: Do not to take any indigestion remedies, iron or zinc supplements at the same time as this medicine.
Generic Name: Lymecycline
Synonyms: Chlorotetracycline; Chlortetracyclinium chloride; Chlortetracycline hydrochloride; Chlortetracycline; Chlortetracyclin; Chlorotetracycline hydrochloride; CLTC; CTC; 7-Chlorotetracycline
Drug Category: Anti-Bacterial Agents; Antiprotozoals
Drug Type: Small Molecule; Approved
Absorption: Absorption is fast and efficient. Bioavailability is 100% following oral administration.
Toxicity (Overdose): Adverse effects include nausea, vomiting, diarrhoea, glossitis, enterocolitis, dysphagia, dermatitis, hypersensitivity reactions, proctitis, and vaginitis.
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Aurofac: Capsule Oral
Chemical IUPAC Name: (2Z,4S,4aS,5aS,6S,12aS)-2-(amino-hydroxymethylidene)-7-chloro-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione
Chemical Formula: C22H23ClN2O8
Lymecycline on Wikipedia: https://en.wikipedia.org/wiki/Lymecycline
Organisms Affected: Enteric bacteria and other eubacteria